[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,555,872
  • Shares Outstanding, K 1,550,908
  • Annual Sales, $ 58,739 M
  • Annual Income, $ 10,225 M
  • EBIT $ 14,315 M
  • EBITDA $ 20,048 M
  • 60-Month Beta 0.24
  • Price/Sales 5.10
  • Price/Cash Flow 14.94
  • Price/Book 6.32

Options Overview Details

View History
  • Implied Volatility 31.64% (+0.37%)
  • Historical Volatility 36.58%
  • IV Percentile 97%
  • IV Rank 82.45%
  • IV High 34.22% on 02/05/26
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 8) 5.13 (2.87%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 6,583
  • Volume Avg (30-Day) 1,610
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 73,159
  • Open Int (30-Day) 75,150
  • Expected Range 173.36 to 183.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.52
  • Number of Estimates 3
  • High Estimate $2.56
  • Low Estimate $2.49
  • Prior Year $2.18
  • Growth Rate Est. (year over year) +15.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
172.76 +3.32%
on 07/09/26
196.41 -9.12%
on 07/02/26
-4.94 (-2.69%)
since 06/09/26
3-Month
172.76 +3.32%
on 07/09/26
207.30 -13.90%
on 04/10/26
-26.50 (-12.93%)
since 04/09/26
52-Week
137.23 +30.07%
on 07/21/25
212.71 -16.09%
on 02/18/26
+36.85 (+26.02%)
since 07/09/25

Most Recent Stories

More News
AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of...

AZN : 178.49 (-5.70%)
Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

ARKG : 43.00 (+2.70%)
AZN : 178.49 (-5.70%)
MRK : 125.07 (-0.73%)
GILD : 134.84 (-0.72%)
TEM : 61.50 (+7.39%)
GSK : 52.47 (-0.10%)
ARKK : 81.53 (+1.71%)
BMY : 57.94 (+0.70%)
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Five-year, multimillion-dollar partnership kicks off with cancer screening and early detection education initiative in 75 communities

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed TRUQAP combination reduced risk of radiographic disease progression or death by 19% ...

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Switching to camizestrant led to a 99% median reduction in total ctDNA vs. a 64% increase for patients who remained on standard of care 51% of patients...

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Positive overall survival trend in favor of STRIDE regimen with lenvatinib and TACE

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of IMFINZI added to BCG vs. BCG alone

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival...

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

EMERALD-3 late-breaking presentation will showcase benefit of IMFINZI ® (durvalumab) and IMJUDO ® (tremelimumab-actl) in early liver...

AZN : 178.49 (-5.70%)
AZN.LN : 13,353.998 (-6.22%)
As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

SSNLF : 140.0000 (+114.69%)
BABA : 111.14 (+1.98%)
AZN : 178.49 (-5.70%)
VXUS : 84.90 (+0.54%)
NVS : 154.62 (-0.35%)
TME : 8.85 (+0.34%)
TSM : 436.96 (unch)
IXUS : 94.82 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 188.99
2nd Resistance Point 184.60
1st Resistance Point 181.54
Last Price 178.49
1st Support Level 174.10
2nd Support Level 169.71
3rd Support Level 166.65

See More

52-Week High 212.71
Fibonacci 61.8% 183.88
Last Price 178.49
Fibonacci 50% 174.97
Fibonacci 38.2% 166.06
52-Week Low 137.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.